Darbepoetin alfa for the treatment of cancer-related anemia: an update

REFERENCES

• Ludwig H, Strasser K. Symptomatology of anemia. Semin. Oncol 28(2), 7–14 (2001).
   PubMed Web of Science ®Google Scholar
• Curt GA, Breitbart W, Cella D et al Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 5(5), 353–360 (2000).
   PubMedGoogle Scholar
• Mercadante S, Gebbia V, Marrazzo A, Filosto S. Anaemia in cancer: pathophysiology and treatment. Cancer 7i-eat. Rev 26(4), 303–311 (2000).
   Google Scholar
• Groopman JE, Itri LM. Chemotherapy- induced anemia in adults: incidence and treatment. Natl Cancer Inst. 91(19), 1616–1634 (1999).
   Google Scholar
• Ludwig H, Barrett-Lee PJ, Gascon P et al European Cancer Anaemia Survey defines factors surrounding anaemia in thousands of adult cancer patients. Proc. Am. Soc. Clin. Oncol 21,387a (2002) (Abstract 1546).
   Google Scholar
• Kirshner J, Hatch M, Hennessy DD, Fridman M, Tannous RE. Anemia in stage II and III breast cancer patients treated with adjuvant doxorubicin and cyclophosphamide chemotherapy. Oncologist 9(1), 25–32 (2004).
   PubMed Web of Science ®Google Scholar
• Rizzo JD, Lichtin AE, Woolf SH et al Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. B/ooc/100(7), 2303–2320 (2002). Proposes and discusses guidelines for epoetin use.
   Google Scholar
• Littlewood TJ, Bajetta E, Nortier J, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. Clin. Oncol 19(11), 2865–2874 (2001).
   Google Scholar
• Vansteenkiste J, Pirker R, Massuti B et al Double-blind, placebo-controlled, randomized Phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. j Natl Cancer Inst. 94(16), 1211–1220 (2002).
   Google Scholar
• ••Phase III trial demonstrating efficacy ofdarbepoetin alfa given once weekly to patients with lung cancer.
   Google Scholar
• Hedenus M, Adriansson M, San Miguel J et al Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. BE j Haematol 122, 394–403 (2003).
   PubMed Web of Science ®Google Scholar
• ••Phase III study demonstrating the efficacyof once-weekly darbepoetin alfa in patients with lymphoproliferative malignancies.
   Google Scholar
• Osterborg A, Brandberg Y, Molostova V et al Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. j Clin. Oncol 20(10), 2486–2494 (2002).
   Google Scholar
• Glaser CM, Millesi W Komek GV et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int. .1. Radiat. Oncol Phys. 50(3), 705–715 (2001).
   Google Scholar
• Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4(8), 459–460 (2003).
   PubMed Web of Science ®Google Scholar
• •Recent trial suggesting that breast cancer patients treated with epoetin had lower 12-month survival than those treated with placebo.
   Google Scholar
• Henke M, Laszig R, Rabe C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362 (9392), 1255–1260 (2003).
   PubMed Web of Science ®Google Scholar
• Bohlius JF, Langensiepen S, Schwarzer G, Bennett CL. Does erythropoietin improve overall survival in the treatment of patients with malignant diseases? Results of a comprehensive meta-analysis. Blooc1102, 203a (2003) (Abstract 709).
   Google Scholar
• Acs G, Acs P, Beckwith SM et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res. 61(9), 3561–3565 (2001).
   Google Scholar
• Westphal G, Braun K, Debus J. Detection and quantification of the soluble form of the human erythropoietin receptor (sEpoR) in the growth medium of tumor cell lines and in the plasma of blood samples. Clin. Exp. Med. 2(1), 45–52 (2002).
   Google Scholar
• Yasuda Y, Fujita Y, Matsuo T et al. Erythropoietin regulates tumour growth of human malignancies. Catrinogenesis 24(6), 1021–1029 (2003).
   PubMed Web of Science ®Google Scholar
• Takeshita A, Shinjo K, Higuchi M et al Quantitative expression of erythropoietin receptor (EPO-R) on acute leukaemia cells: relationships between the amount of EPO-R and CD phenotypes, in vitro proliferative response, the amount of other cytokine receptors and clinical prognosis. Japan Adult Leukaemia Study Group. Br. 1-Lematol. 108(1), 55–63 (2000).
   Google Scholar
• Westenfelder C, Baranowski RL. Erythropoietin stimulates proliferation of human renal carcinoma cells. IGthrey Int. 58(2), 647–657 (2000).
   Google Scholar
• Brower V. Normal and neoplastic prostate cells have EPO receptors. Lancet Oncol 4(2), 69 (2003).
   PubMed Web of Science ®Google Scholar
• Berdel WE, Oberberg D, Reufi B, Thiel E. Studies on the role of recombinant human erythropoietin in the growth regulation of human nonhematopoietic tumor cells in vitro. Ann. Hematol 63(1), 5–8 (1991).
   PubMed Web of Science ®Google Scholar
• Rosti V, Pedrazzoli P, Ponchio L et al Effect of recombinant human erythropoietin on hematopoietic and non-hematopoietic malignant cell growth in vitro. I-Lematologica 78 (4), 208–212 (1993) .
   PubMed Web of Science ®Google Scholar
• Li K, Menon MP, Karur VG, Hegde S, Wojchowski DM. Attenuated signaling by a phosphotyrosine-null Epo receptor form in primary erythroid progenitor cells. Blood 102(9), 3147–3153 (2003).
   PubMed Web of Science ®Google Scholar
• Haroon ZA, Amin K, Jiang X, Arcasoy MO. A novel role for erythropoietin during fibrin-induced wound-healing response. Am. Pathol 163(3), 993–1000 (2003).
   PubMed Web of Science ®Google Scholar
• Amgen, Inc. Amnes, (darbepoetin alfa) Prescribing- Information. Amgen, Inc., Thousand Oaks, CA, USA (2002).
   Google Scholar
• Hoffmann-La Roche. NeoRecormon° Package Leaflet. Hoffmann-La Roche, Basel, Switzerland (2000).
   Google Scholar
• Ortho Biotech Products LP Procri? (epoetin alfa) Prescribing Information. Ortho Biotech Products LP, Bridgwater, NJ, USA (2000).
   Google Scholar
• Gabrilove JL, Cleeland C, Livingston RB, Sarokhan B, Winer E, Einhorn L. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. 1 Clin. Oncol 19(11), 2875–2882 (2001).
   Google Scholar
• Schwartzberg L, Shiffman R, Tomita D, Stolshek B, Rossi G, Adamson R. A multicenter retrospective cohort study to compare the utilization patterns and clinical outcomes of erythropoietic proteins for chemotherapy-induced anemia. Clin. Ther. 25(11), 2781–2796 (2003).
   PubMed Web of Science ®Google Scholar
• Cazzola M, Beguin Y, Kloczko J, Spicka I, Coiffier B. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. BE j I-Lematol 122 (3), 386–393 (2003).
   PubMed Web of Science ®Google Scholar
• Glaspy JA, Jadeja JS, Justice G et al Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. BE j Cancer 87 (3), 268–276 (2002).
   Google Scholar
• Kotasek D, Steger G, Faught W et al Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur. Cancer39(14), 2026-2034 (2003).
   Google Scholar
• ••Initial trial demonstrating feasibility andefficacy of darbepoetin alfa dosing once every 3 weeks in patients with chemotherapy-induced anemia.
   Google Scholar
• Rearden T, Charu V, Saidman B et al Results of a randomized study of every three-week dosing (Q3W) of darbepoetin alfa for chemotherapy-induced anemia (CIA). 13119C. A117. Soc. Clin. Oncol 23,741 (2004) (Abstract 8064).
   Google Scholar
• •Recent results from a study of darbepoetin alfa given every 3 weeks to patients with chemotherapy-induced anemia.
   Google Scholar
• Schwartzberg L, Lorrin Y, Senecal F, Charu V, Tomita D, Rossi G. Darbepoetin alfa (DA) 200 mcg every 2 weeks (Q2W) vs. epoetin alfa (Epo) 40,000 U weekly (QW) in anemic patients (pts) receiving chemotherapy (ctx). Proc. Am. Soc. Clin. Oncol 23,741 (2004) (Abstract 8063).
   Google Scholar
• •First head-to-head comparison of every-2-weeks darbepoetin alfa and once-weekly epoetin.
   Google Scholar
• Vadhan-Raj S, Mirtsching B, Charu V et al Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every 2 weeks. j Support. Oncol 1(2), 131–138 (2003).
   Google Scholar
• Vadhan-Raj S, Mirtsching B, Gregory SA et al Baseline (BL) covariates of response to darbepoetin alfa (DA) every 2 weeks (Q2W) in patients (pts) with chemotherapy-induced anemia (CIA). Proc. Arn. Soc. Clin. Oncol 23,740 (2004) (Abstract 8061).
   Google Scholar
• Thames WA, Smith SL, Schiefele AC, Yao B, Giffin SA, Alley JL. Evaluation of the US Oncology Network's recommended guidelines for therapeutic substitution with darbepoetin alfa: 200 pg every 2 weeks in both naive patients and patients switched from epoetin alfa. Pharmacotherapy24(3), 313–323 (2004).
   Google Scholar
• Tauer K, Zhu L, Fortner B. The impact of anemia treatment visits on the patient and their caregiver. Proc. Arn. Soc. Clin. Oncol 23,753 (2004) (Abstract 8114).
   Google Scholar
• Beveridge RA, Rifkin RM, Moleski RJ et al Impact of long-acting growth factors on practice dynamics and patient satisfaction. Pharmacotherapy23(12 Pt 2), 101S-109S (2003).
   Google Scholar
• Pirker R, Smith R. Darbepoetin alfa: potential role in managing anemia in cancer patients. Expert Rev Anticancer Ther. 2 (4), 89–96 (2002).
   Google Scholar
• Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). BE j Cancer 84\(Suppl. 1), 3–10 (2001).
   Google Scholar
• Glaspy J, Henry D, Patel R et al A randomized trial evaluating the pharmacologic and hematologic effects of the timing of darbepoetin alfa and chemotherapy administration. Blood 102(11), 9B (2003) (Abstract 3737).
   Google Scholar
• Heatherington AC, Schuller J, Kotasek D et al Changes in endogenous erythropoietin and the pharmacokinetics of darbepoetin alfa in patients with nonmyeloid malignancies receiving or not receiving chemotherapy. B/ooc/98(11), 298a (2001).
   Google Scholar
• Vansteenkiste J, Tomita D, Rossi G, Pirker R. Darbepoetin alfa in lung cancer patients on chemotherapy: a retrospective comparison of outcomes in patients with mild versus moderate-to-severe anaemia at baseline. Support Care Cancer 12 (4), 253–262 (2004).
   PubMed Web of Science ®Google Scholar
• Cella D, Elton D, Lai JS. Combining anchor and distribution based methods to derive clinically meaningful differences on the Functional Assessment of cancer Therapy (FACT) Anemia and Fatigue scales. .1. Pain Symptom. Manage. 24(6), 547–561 (2002).
   Google Scholar
• Thatcher N, De Campos ES, Bell DR et al Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. BE j Cancer 80 (3/4), 396–402 (1999).
   Google Scholar
• Bamias A, Aravantinos G, Kalofonos C et al Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human erythropoietin (rHuEpo): a prospective, open label, randomized trial by the Hellenic Co-operative Oncology Group. Oncology 64(2), 102–110 (2003).
   PubMed Web of Science ®Google Scholar
• Glaspy JA, Jadeja JS, Justice G, Fleishman A, Rossi G, Colowick AB. A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease. Cancer97 (5), 1312–1320 (2003).
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Arena F, Patel D et al A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. Cancer 100 (4), 859–868 (2004).
   PubMed Web of Science ®Google Scholar
• Smith RE, Tchekmedyian NS, Chan D et al. A dose-finding and schedule-finding study of darbepoetin alfa for the treatment of chronic anaemia of cancer. BE j Cancer 88(12), 1851–1888 (2003). Explores the use of darbepoetin alfa in patients with anemia of cancer.
   Google Scholar
• Charu V, Belani CP, Gill AN et al. A controlled, randomized, open-label study to evaluate the effect of every-2-week darbepoetin alfa for anemia of cancer. Proc. Am. Soc. Clin. Oncol 23, 741 (2004) (Abstract 8084).
   Google Scholar
• Patton J, Reeves T, Wallace J. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice. Oncologist 9 (4), 451–458 (2004) .
   PubMed Web of Science ®Google Scholar
• Cleeland CS, Crawford J, Lubeck D, Tomita D, SURPASS Study Group. Using the MD Anderson Symptom Inventory (MDASI) to assess symptom burden and interference: interim results of an open-label study of darbepoetin alfa 200 mcg every 2 weeks (Q2W) for the treatment of chemotherapy-induced anemia (CIA). Proc. Am. Soc. Clin. Oncol 23, 741 (2004) (Abstract 8065).
   Google Scholar
• Hedenus M, Rossi G, Hendricks L, Vansteenkiste J. Darbepoetin alfa is well tolerated with no long-term safety or survival concerns in patients with cancer undergoing chemotherapy: evidence from two Phase III trials. Support. Carr Cancer 12(6), 397–398 (2004) (Abstract 250).
   Google Scholar
• Kirkpatrick JP, Snyder SA, Zhao Y et al. Oxygenation of a rodent adenocarcinoma is improved by darbepoetin alfa. Int. Congress Radiat. Res. (2003) (Abstract P05/1690).
   Google Scholar
• Ning S, Hornung B, Knox SJ. Darbepoetin alfa (Aranesp) potentiates the efficacy of radiation therapy in vivo. Proc. Am Assoc. Cancer Res. 44, 1345–1346 (2003) (Abstract LB–113).
   Google Scholar
• National Comprehensive Cancer Network. NCCN practice guidelines in oncology: cancer and treatment-related anemia. Version 2.2004 (2004) www.nccn.org (Accessed September 2004)
   Google Scholar